AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry
Heartflow announced prospective one-year outcomes from the DECIDE registry showing its AI Plaque Analysis cut major cardiovascular events by 34% and myocardial infarction rate by half versus CCTA alone in more than 6,000 matched patients. The event reductions were linked to earlier therapy optimization: 50% of patients reached LDL-C goal (<70 mg/dL) by 90 days versus 35% with CCTA alone, with management changed in over 50% of patients. A second registry (GAMEFILM) found detectable coronary plaque in 85% of 200 retired NFL players, most of it soft plaque invisible to calcium scoring, and the registry is expanding to MLB and college sports.
Key figures
- Drug Name
- Heartflow Plaque Analysis with Plaque Staging
- Phase Of Trial
- Prospective DECIDE registry (real-world outcomes)
- Mi reduction
- 50% at one year
- Decide patients
- 6000
- Gamefilm players
- 200
- Ldlc goal 90days
- 50% vs 35% with CCTA alone
- Cvd event reduction
- 34%
- Ldlc reduction 90days mgdl
- 18.7
- Plaque prevalence retired nfl
- 85%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.